Podcasts about cgrp

Why do so many migraine attacks come with nausea, bloating, stomach discomfort, or digestive shutdown?In this episode of The Migraine Heroes Podcast, host Diane Ducarme explores the powerful connection between migraines and the gut-brain axis. Blending neuroscience with holistic healing perspectives, this episode reveals why nausea is not “just a symptom,” but often part of the migraine process itself.You'll discover:

We break down migraines as a neurologic condition with a real brain-based chain reaction, not a character flaw or a one-off “bad headache.” We share practical prevention habits, how to track triggers, and how acute and preventive migraine medications fit together so you can walk into your next visit prepared. • what makes a migraine different from other headache types • common and less common migraine presentations including aura and scary look-alikes • the five-step migraine chain reaction including CGRP and pain amplification • high-yield triggers like stress, sleep changes, skipped meals, hormones, smells, and weather shifts • consistency as the core prevention theme across sleep, exercise, eating, and stress • migraine diary basics to identify patterns and improve your neurologist visit • when headaches warrant a call to a clinician and what red flags to take seriously • acute treatment options including OTC meds, triptans, CGRP blockers, and anti-nausea meds • medication overuse headache risk when acute meds are used too often • preventive options including beta blockers, anti-seizure meds, antidepressants, and Botox You can find us on Threads, you could send us an email, or you can send us some fan mail. We still have that voice-based fan mail still waiting for that first fateful one. Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory. The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development. Looking for more Headache & migraine discussion? Check out the NeurologyLive® Headache & migraine clinical focus page.Episode Breakdown: 1:10 – PROCEED trial efficacy in patients with prior preventive failures 5:10 – Safety and tolerability findings for bocunebart 6:30 – Coadministration data with ubrogepant and clinical implications 8:30 – Neurology News Network  10:50 – Rationale for combining PACAP and CGRP-targeted therapies 13:40 – Key considerations for future phase 3 development The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease FDA Grants Priority Review to Bayer's Asundexian for Secondary Stroke Prevention Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

In this episode of Talk Dizzy To Me, vestibular physical therapists Dr. Abbie Ross, PT, NCS and Dr. Danielle Tolman, PT sit down with neurologist Dr. Kristin Steenerson to unpack Persistent Postural Perceptual Dizziness, also known as 3PD or PPPD.If you feel dizzy, floaty, rocking, disoriented, or visually overwhelmed most days — especially in places like grocery stores, airports, busy restaurants, or while scrolling screens — this episode explains what may be happening in the brain and nervous system.Dr. Steenerson breaks down the diagnostic criteria for 3PD, why symptoms can continue even after the original vestibular problem improves, how 3PD overlaps with vestibular migraine, and why treatment often requires a combination of education, vestibular therapy, medication, cognitive strategies, lifestyle support, and gradual exposure.This conversation also addresses why 3PD is sometimes misunderstood, how hypervigilance plays a role, and why there is real hope for recovery and improved quality of life. Hosted by:

Migraines are often dismissed as “just a bad headache,” but they can be much more serious and disruptive. So what actually causes migraines, and when should someone stop trying to push through the pain?In this episode of Baptist Health Talk, host Sandra Peebles speaks with Dr. Maria Vera Silva, neurologist at Baptist Health Miami Neuroscience Institute, and Dr. Andrew Forster, internal medicine physician at Baptist Health Primary Care, about what migraines are, how they affect the brain, and why treatment is not one size fits all.In this conversation, they discuss: Why migraines are considered a neurologic disease  How migraines differ from regular headaches  Common triggers, including stress, hormones, sleep changes, foods and weather  The connection between migraines and mental health  Treatment options, including anti inflammatories, triptans, CGRP inhibitors and Botox  What to know about viral migraine “hacks” on social media  When migraine symptoms should prompt a visit to a doctor Migraines can interfere with work, school, family life and everyday activities. Understanding the signs, triggers and treatment options can help patients get the right care sooner.For more health and wellness information, visit Baptist Health South Florida's resource blog: baptisthealth.net/newsHost:Sandra PeeblesAward-Winning JournalistGuest:Maria Andreina Vera Silva, M.D. NeurologistBaptist Health Miami Neuroscience InstituteAndrew Forster, M.D. Internal Medicine Physician Baptist Health Primary CareIf you found this episode helpful, you may also enjoy:A 'Heads Up' on Migraine & Headache Disorders

Drs. Chandwani and Kuruvilla explain that migraine and facial pain often share trigeminal system mechanisms, leading to frequent misdiagnosis as dental, musculoskeletal, or sinus problems, possibly resulting in unnecessary procedures. The speakers emphasize CGRP-targeted therapies, careful mechanism-based diagnosis, and multidisciplinary collaboration across neurology, orofacial pain, physical therapy, and behavioral health to improve outcomes for patients with complex facial pain and migraine presentations.

In this episode, I'm talking about something I'm not hearing many people in the migraine space discuss openly, Botox as a preventative treatment for chronic migraines. My goal isn't to scare you or tell you what to do. My goal is to make sure you have the full picture before you make a decision about what goes into your body. I explain what Botox actually is, how it works in your body, why the migraine protocol uses far higher doses than cosmetic Botox, and the long-term concerns I have around muscle atrophy, neck function, CGRP, and your body's overall toxic load. I also share why I believe neck pain is often a symptom of migraines rather than the cause, and what I recommend focusing on instead if you want real, long-term healing. If you haven't yet listened to my previous episode on trigger point injections, I highly recommend pairing these two together, they build on each other and give you a fuller understanding of what's really driving your chronic migraines.Check out the podcast episode about trigger point injections: Trigger Point Injections and Migraines. What Nobody Tells YouIf you're ready to address the root drivers of your migraines, you can book a free consultation at the link below: https://www.drlesliecisar.com/apply Free Training: 5 Proven Steps to Being Migraine Free (Even if you think you've already tried everything.) https://www.drlesliecisar.com/5SHMN Connect with us: Website: https://www.drlesliecisar.com/ Free Facebook Group: Healing Migraines Naturally, with Leslie Cisar, ND Ready to try something radically different that actually works? Read more about my approach here: https://www.drlesliecisar.com/map In health,Dr. Leslie Cisar

In dieser Episode von "Der Schmerzcode" widmen wir uns dem Thema Migräne, einer weit verbreiteten neurologischen Erkrankung, die mehr als eine Milliarde Menschen betrifft. Gemeinsam mit Till, einem zertifizierten Kopfschmerzexperten, betrachten wir die Fortschritte in der Migräneforschung und -behandlung der letzten zwei Jahrzehnte. Wir erläutern die Pathophysiologie, die verschiedenen Arten von Migräne und die Unterschiede zwischen episodischer und chronischer Migräne. Besonderes Augenmerk liegt auf den Triggern wie Stress und Ernährung, sowie den Herausforderungen, vor denen Patienten stehen. Wir diskutieren die verfügbaren Behandlungsmöglichkeiten, einschließlich akuter und prophylaktischer Therapien sowie nicht-medikamentöser Ansätze. Abschließend reflektieren wir über die aktuellen Entwicklungen in der Migräneforschung und die gesellschaftliche Wahrnehmung dieser ernsthaften Erkrankung.

Drs. Kuruvilla and Chandwani discuss migraine as a key women's health issue driven largely by estrogen fluctuations across a woman's lifespan, influencing CGRP, serotonin, sleep, and comorbid pain conditions from menstruation through perimenopause and menopause. These experts emphasize individualized, interdisciplinary care that combines CGRP-targeted preventives, hormonal strategies, integrative medicine (eg, acupuncture, supplements), and lifestyle and sleep optimization to improve quality of life.

Every spring, something shifts. The air changes, your body reacts… and your migraines may quietly follow.In this episode of Migraine Heroes Podcast, host Diane Ducarme explores the often-overlooked connection between pollen allergies and migraine patterns. What you may dismiss as “just hay fever” could be placing hidden stress on your nervous system—and lowering your threshold for migraine attacks.Blending neuroscience with a holistic lens, this episode helps you understand how seasonal changes influence your brain, your immune system, and your pain.You'll discover:

What if preventing migraines didn't require drastic changes—but small ones repeated consistently?In this episode of Migraine Heroes Podcast, host Diane Ducarme explores how the concept of atomic habits can transform migraine prevention. While many people search for a single trigger, migraine brains often react to the accumulation of tiny daily stresses: poor sleep, dehydration, skipped meals, emotional strain, or screen overload—until the brain crosses its migraine threshold.Inspired by the philosophy of small, consistent actions popularized in behavioral science, Diane explains how tiny daily habits can gradually strengthen your nervous system and help stabilize the sensitive migraine brain. By blending neuroscience, lifestyle medicine, and practical experience from working with migraine sufferers, this episode reveals why consistency beats intensity when it comes to protecting your brain.You'll learn:

What are your options for migraine prevention, and how do you choose the right one?   In Part 2 of this two-part Spotlight on Migraine series, host Molly O'Brien and headache specialist Dr. Jessica Ailani dive into the full range of migraine prevention treatments available today.   Dr. Ailani breaks down lifestyle modifications, neuromodulation, CGRP-targeted treatments, onabotulinumtoxinA, supplements, and more. She discusses combination treatment and options for menstrual migraine. With good migraine prevention, you can stop chasing attacks and gain back some control over attack frequency.   Be sure to listen to Part 1 for a discussion on when to start prevention and how to measure success: https://www.migrainedisorders.org/pod...   Read the transcript at: https://www.migrainedisorders.org/podcast/s8e4-migraine-preventive-options/   *The contents of this podcast are intended for general informational purposes only and do not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. AMD and the speaker do not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.

You've heard it before: “Stress triggers migraines.” But here's what most people don't realize , not all stress is created equal.In this episode of Migraine Heroes Podcast, host Diane Ducarme breaks down the five core faces of stress and reveals how each one activates a different pathway in your brain and body. Because the stress of pressure and performance does not impact your nervous system the same way as grief, overstimulation, or emotional tension.When you identify which stress pattern is driving your attacks, you move from vague advice to precise action.In this episode, you will learn:

Dr. Jessica Ailani and Dr. Richard Lipton discuss future advancements in headache medicine.  Show transcript:  Dr. Jessica Ailani:  Hello and welcome to the Neurology Minute. I'm Jessica Ilani from Georgetown Headache Center in Washington, DC. In the neurology podcast with Richard Lipton from the Montefiore Headache Center, we'll be discussing the latest clinical trials in headache medicine, where our field is going, where it's been, and you'll get lots of great advice on thinking through a clinical trial, what the advances have been, where their pitfalls have been, and really how to think of both positive and negative trials. So Richard, what are you most looking forward to when it comes to new treatment targets within headache? Dr. Richard Lipton:  First, let me say that I'm sure most know about the eight CGRP targeted treatments have been approved for migraine, both as acute and preventive treatments. And it's very clear that those treatments have had incredible benefits for our patients and have really improved headache practice. There's another neuropeptide target also targeted by monoclonal antibodies called PACAP or pituitary adenolyte cyclase activating polypeptide. This peptide is also a potent vasodilator involved in pain signaling like CGRP. While CGRP is primarily linked to sensory pathways, PACAP is found in parasympathetic ganglia. And for that reason, it may have a special role in headaches associated with cranial autonomic symptoms. And that includes both migraine, which commonly has cranial autonomic symptoms and also cluster headache. There's a recent randomized trial published in New England Journal showing that a monoclonal antibody targeting PACAP reduced monthly migraine day frequency and was beneficial in people who failed to respond to CGRP inhibitors. So that's at least one area that I'm hopeful about. Dr. Jessica Ailani:  So Richard, thank you so much. I hope you have a few moments and listen to our full podcast that'll tell you a lot more about the future of headache medicine. 

In part one of this series, Dr. Tesha Monteith and Dr. Jennifer Robblee discuss an international consensus definition for refractory migraine and why clearer criteria are needed.  Show citations: Robblee J, Minen MT, Friedman BW, Cortel-LeBlanc MA, Cortel-LeBlanc A, Orr SL. 2025 Guideline Update to Acute Treatment of Migraine for Adults in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2026;66(1):53-76. doi:10.1111/head.70016 Robblee J, Khan FA, Marmura MJ, et al. Reaching International Consensus on the Definition of Refractory Migraine Using the Delphi Method. Cephalalgia. 2025;45(9):3331024251367767. doi:10.1177/03331024251367767 Show transcript:  Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Jennifer Robblee about her exciting work defining refractory migraine with an international consensus, as well as her work with the American Headache Society on a guideline update for parental pharmacotherapies for migraine in the emergency department. Hi, Jennifer. Thanks again for coming on our Neurology Minute. Dr. Jennifer Robblee: Thank you so much for having me. I'm delighted to be here. Dr. Tesha Monteith: You've done a lot of work in the area of refractory migraine. Why don't you tell us why you felt there need to be clarification on the definition? Dr. Jennifer Robblee: Well, this is a patient population that I'm really passionate about. There's not enough research out there. We don't really know who these patients are, why they're not responding to treatment, and we don't know how to help them because we have no guidelines, obviously, since they're refractory to what we use for treating. So I thought it was really good to get an international group to standardize our definition and hopefully help move the research forward. Dr. Tesha Monteith: Why don't you tell us a little bit about the consensus definition Dr. Jennifer Robblee: So we came up with an international consensus definition for refractory migraine that was laid out the same way that migraine is, say, laid out in the ICHD-3 diagnostic manual, if you want to call it that. So we have different criteria on. So criterion A basically allowed for it to be episodic or chronic migraine. Criterion B had three subcriteria, so you needed to have at least two out of three of severe to very severe disability and/or a constant background headache and/or at least eight monthly migraine days. Criterion C was about the lack of response to treatment. And basically it says that you needed to have failure of all medication categories, and there is an extra one for an other in case any new treatments emerge before the diagnostic criteria get updated. And what we considered a, quote, unquote, failure was that you did not have a 50% improvement in monthly migraine days, or you had intolerable side effects, or you had an absolute contraindication. There is a caveat that you need to have at least four true lack of efficacies. And then the CGRP monoclonal antibody or gepant category and the onabotulinumtoxin toxin category both had to be a true lack of response. And of course, there's a criterion B to say that this should not be from another diagnosis. Dr. Tesha Monteith: Thanks so much, Jennifer.

"CGRP Targeting Treatments: A Valuable Addition to the Migraine Armamentarium." From ASRA Pain Medicine News, February 2026. See the original article at www.asra.com/february26news for figures and references. This material is copyrighted.Support the show

Dr. Tesha Monteith and Dr. Patricia Pozo-Rosich discuss the latest advancements in headache medicine, focusing on key research findings from 2025.  Show transcript: Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. Welcome to our 2026 Headache Medicine Series. I've just been speaking with Patricia Pozo-Rosich about all of the exciting advances in headache medicine in 2025. For a minute, why don't you summarize some of the key advances in headache medicine research? Dr. Patricia Pozo-Rosich: I think that we have good news in headache. We are currently phase two trials for two or three different compounds, anti-part two, packup and new toxins. So we are actually, I think, excited to find out the phase 2B trial results and phase three. So well, that's something that I think is worth mentioning. Then I think it is important to remember that we have new data coming from real world evidence with long-term use of anti CGRP therapies. We also have data that shows that anti CGRP therapies are useful for patients with migraine and major depressive disorder, as well as as children. Finally, I think that it is very important to remind everyone that there are new papers on practice recommendations around the world on how we have to treat our patients with migraine, and that is related both to the acute and preventive therapies. And finally, couple of position statements that have been written by the International Hague Society that strive to improve the quality of how migraine individuals are treated, and that really conveys a paradigm shift where we probably should be starting preventive therapy sooner than later. Dr. Tesha Monteith: Great. Thank you so much for that quick summary. And please check out the Full Headache Medicine series. I appreciate talking to you, Patricia, and look forward to discussing more highlights next time. Dr. Patricia Pozo-Rosich: Thank you, Tisha. See you very soon. Dr. Tesha Monteith: And thank you for listening to the Neurology Minutes.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Amaal Starling, MD, FAHS, FAAN, joins the podcast to provide clinical perspective on the INFUSE real world study evaluating IV eptinezumab in adults with migraine who previously found one or more CGRP preventive options ineffective, based on data presented at the 2026 Headache Cooperative of the Pacific Annual Conference. Starling, an associate professor of neurology at Mayo Clinic College of Medicine and a study author on INFUSE, discusses how clinicians should interpret the magnitude of benefit in a high burden population and why IV delivery, including rapid and consistent bioavailability, may help explain early and sustained response. The conversation also explores what the findings suggest for real world care and treatment sequencing, how migraine trials can better capture patient experience through outcomes like good days and PGIC, and what precision medicine research could look like next as the field pushes toward predictive modeling and individualized treatment selection.Looking for more Headache & Migraine discussion? Check out the NeurologyLive® Headache & Migraine clinical focus page.Episode Breakdown: 1:20 – Interpreting real world response after prior CGRP preventive failure 4:25 – Mechanistic reasons IV eptinezumab may drive early sustained benefit 6:25 – Clinical implications for earlier, more robust treatment sequencing 8:50 – Neurology News Network  11:20 – Integrating good days and Patient Global Impression scales into migraine trial design 15:30 – Future studies needed to advance precision migraine care The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Fenebrutinib Achieves Primary End Point in Phase 3 Head-to-Head Trial vs Teriflunomide in Relapsing MS Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies Efgartigimod Meets Primary End Point in Phase 3 ADAPT OCULUS Study of Ocular Myasthenia Gravis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Drs. Ailani and Dougherty discuss onabotulinumtoxinA, a cornerstone treatment for chronic migraine, which reduces headache days and disability when given regularly with the PREEMPT protocol. They emphasize its unique benefits and how it pairs with CGRP therapies, oral preventives, and lifestyle changes for individualized care.

In this episode, Senior Editor Morgane Boillot speaks with Professor Cristina Tassorelli (University of Pavia, Italy) about recent advances in migraine prevention. Together with colleagues, Tassorelli has authored a Review in the journal examining the major developments in migraine-specific pharmacological treatments over the past decade, with a particular focus on therapies targeting the CGRP pathway. In this conversation, they explore what these advances mean for people living with migraine and for clinicians, discuss promising emerging targets for prevention and the future of biomarkers, and consider whether it is time to redefine the goals of migraine prevention with greater ambition. Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00477-6/fulltextMedical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In part one of this two-part series, Dr. Tesha Monteith and Dr. Andrew Hershey summarize findings from the SPACE trial evaluating fremanezumab in adolescents and children with migraine. Show citation: Hershey AD, Szperka CL, Barbanti P, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med. 2026;394(3):243-252. doi:10.1056/NEJMoa2504546  Show transcript:  Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I'm here with Andrew Hershey, Professor of Pediatrics and Director of the Division of Neurology at Cincinnati Children's and the Children's Headache Center. We're here talking about his new paper published in the New England Journal of Medicine, Fremanezumab in Children and Adolescents with Episodic Migraine. Andrew, thank you for being on our Neurology Minutes. Dr. Andrew Hershey: Thank you for inviting me. Dr. Tesha Monteith: Can you summarize the findings of the space trial investigating Fremanezumab for adolescents and children with migraine? Dr. Andrew Hershey: This is one of the four monoclonal antibodies against CGRP, or it's this receptor that had been proven effective for adults. And it's the first one, the formazepam, that's been able to report its effectiveness in children and adolescents with less than 15 headache days per month. This study looked at over 200 children adolescents that were in a double-blinded randomized placebo controlled study. And reached its primary, as well as its secondary endpoint of a reduction compared to placebo. And the number of attacks of migraine per month, as well as a greater than 50% reduction in the number of headache attacks per month, with minimal to no side effects, the most notable side effect being injection site erythema. Dr. Tesha Monteith: Great. Thank you so much for providing that update. Do check out the full podcast for more details about his paper and the treatment of migraine in children and adolescents. This is Tesha Monteith. Thank you for listening to the Neurology Minute.  

Dr. Tesha Monteith and Dr. Michael Eller discuss the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke.  Show citation: Eller MT, Schwarzová K, Gufler L, et al. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review. Neurology. 2025;105(2):e213852. doi:10.1212/WNL.0000000000213852  Show transcript:  Dr. Tesha Monteith: Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Michael Eller from the Department of Neurology Medical University of Innsbruck, Austria on the neurology podcast on his paper, CGRP Targeted Migraine Therapies in Patients with Vascular Risk Factors or Stroke: A Review. Hi, Michael. Dr. Michael Eller: Hello. Dr. Tesha Monteith: Why don't you summarize your general approach to use of CGRP targeted therapies in patients that might be at risk for vascular events when considering safety? Dr. Michael Eller: Yeah. About acute vascular events, we should stop CGLP targeted drugs immediately. When we come to post-stroke, we should reassess the necessity of these targeted treatments after recovery. We suggest a minimum of three months pause after ischemic stroke to allow early recovery and remodeling, and then restart only after individualized benefit risk review. In high-risk primary prevention, so no stroke yet, but elevated risk, if the patients are 65 years or older with established cardiovascular disease, we should prefer traditional preventives. And if CGLP targeted therapy is essential, we should consider Gepants cautiously due to their shorter half lives. We should avoid CGLP targeted treatments in small vessel disease, distal stenosis, Raynaud's phenomenon, and uncontrolled hypertension. For acute migraine treatment, we can consider gepants or ditans as alternatives to triptans and NSAIDs in relevant stroke risk or post-stroke patients, individualized to comorbidities. Dr. Tesha Monteith: Great. And we should say that the label updates include hypertension and Raynaud's phenomenon as potential vascular complications. Otherwise, these are more theoretical risks based on what we know about CGRP. Dr. Michael Eller: Yes, I totally agree because large studies did not show any elevated cardiovascular risk signals. And for post-marketing databases, we did not see any elevated cardiovascular risk so far. However, in pre-clinical settings, studies showed large infarct size in pretreated mice. Dr. Tesha Monteith: Great. Well, thank you again for doing this work. It was a phenomenal read and congratulations. Dr. Michael Eller: Thank you. Dr. Tesha Monteith: This is Tesha Monteith. Thank you for listening to the Neurology Minute.

Dr. Tesha Monteith talks with Dr. Michael Eller about the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Estima-se que em torno de 15% da população mundial sofra de enxaqueca, com maior prevalência nas mulheres - e muitos sintomas, tais como aura, além de hipersensibilidade à luz, ao som e ao cheiro... Afinal, o que a ciência tem a dizer sobre o tema?Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.>> OUÇA (60min 43s)Convidado: Dr. Fabiano Moulin de MoraesMédico neurologista pela Escola Paulista de Medicina da UNIFESP, onde é preceptor da residência em Neurologia. Membro titular da Academia Brasileira de Neurologia, Professor da Casa do Saber e Especialista em neurologia da cognição e do comportamento. Participou do Naruhodo Entrevista 48.* Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*APOIO: INSIDERIlustríssima ouvinte, ilustríssimo ouvinte do Naruhodo, janeiro é tempo de recomeços - e o recomeço mais importante é o momento em que acordamos, todos os dias.Afinal, a escolha da manhã muda tudo:- Vestir a roupa de treino assim que acorda — mesmo treinando só à tarde — aumenta a chance de cumprir a meta.- Colocar uma peça inteligente para trabalhar ou criar conteúdo te coloca instantaneamente em modo produtivo e confiante.- Mesmo para ficar em casa, trocar o pijama por um look confortável e bonito muda o humor, a energia e a presença.Ou seja: a Insider entra no seu ritual matinal e acompanha sua rotina com naturalidade.Então use o endereço a seguir pra já ter o cupom NARUHODO aplicado ao seu carrinho de compras: são 10% de desconto, ou 15% de desconto caso seja sua primeira compra.>>> creators.insiderstore.com.br/NARUHODOOu clique no link que está na descrição deste episódio.E bons recomeços pra você!INSIDER: inteligência em cada escolha.#InsiderStore*REFERÊNCIASMigraine Triggers: An Overview of the Pharmacology, Biochemistry, Atmospherics, and Their Effects on Neural Networkshttps://pmc.ncbi.nlm.nih.gov/articles/PMC8088284/Migraine and cognitive dysfunction: a narrative reviewhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11657937/Structural and Functional Brain Changes in Migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC8119592/Migraine: Multiple Processes, Complex Pathophysiologyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4412887/Migraine management: Non-pharmacological points for patients and health care professionalshttps://www.degruyterbrill.com/document/doi/10.1515/med-2022-0598/htmlIs there a causal relationship between stress and migraine? Current evidence and implications for managementhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8685490/The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Regionhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11751287/Practical issues in the management of sleep, anxiety, and mood disorders in primary headacheshttps://pmc.ncbi.nlm.nih.gov/articles/PMC12221693/Differentiating Visual Symptoms in Retinal Migraine and Migraine With Aura: A Systematic Review of Shared Features, Distinctions, and Clinical Implicationshttps://pmc.ncbi.nlm.nih.gov/articles/PMC12380025/Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategieshttps://pmc.ncbi.nlm.nih.gov/articles/PMC11940401/Migrainehttps://www.nejm.org/doi/10.1056/NEJMra1915327Pratice guideline update summary: Acute treatment of migraine in children and adolescentshttps://www.neurology.org/doi/10.1212/WNL.0000000000008095Migraine aura as an artistic resource https://nah.sen.es/vmfiles/vol13/NAHV13N22025102_115EN.pdfMigraine aura as artistic inspiration.https://pmc.ncbi.nlm.nih.gov/articles/PMC1838881/Migraine as a source of artistic inspirationhttps://neuro.org.br/pdfs/RBN-59/RBN-594-DEZEMBRO/RBN-594-DEZEMBRO.pdf#page=44Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysishttps://pmc.ncbi.nlm.nih.gov/articles/PMC12534955/Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysishttps://pmc.ncbi.nlm.nih.gov/articles/PMC11409395/The impacts of migraine on functioning: Results from two qualitative studies of people living with migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC10922598/Exploring the Hereditary Nature of Migrainehttps://pmc.ncbi.nlm.nih.gov/articles/PMC8075356/Transient receptor potential melastatin 8 (TRPM8) is required for nitroglycerin and calcitonin gene-related peptide induced migraine-like pain behaviors in micehttps://pmc.ncbi.nlm.nih.gov/articles/PMC9519811/Association between weather conditions and migraine: a systematic review and meta-analysishttps://link.springer.com/article/10.1007/s00415-025-13078-0Evaluation of Green Light Exposure on Headache Frequency and Quality of Life in Migraine Patients: A Preliminary One-way Cross-over Clinical Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8034831/CGRP — The Next Frontier for Migrainehttps://www.nvvg.nl/files/3306/CGRP%20—%20The%20Next%20Frontier%20for%20Migraine.pdfDigital Media Use in Adolescents with Migraine: A Topical Reviewhttps://link.springer.com/article/10.1007/s11916-025-01444-6Placebo Response in Acute and Prophylactic Treatment of Migrainehttps://www.neurologic.theclinics.com/article/S0733-8619(25)00068-4/abstractCalcitonin Gene–Related Peptide Inhibitors and Cardiovascular Events in Patients With Migrainehttps://www.neurology.org/doi/abs/10.1212/WNL.0000000000214479?casa_token=WccpvEByt0MAAAAA:LKbxQClihNe2WsrHRKBmteHftcUECeozPKYcnSQPjsBA0hlEvKExc2DvBgn-J5WwWyudd3QV1nluWwInsights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesishttps://journals.sagepub.com/doi/10.1177/03331024241287224Elucidating the susceptibility genes between insomnia and migraine by integrating genetic data and transcriptomeshttps://link.springer.com/article/10.1186/s10194-025-02249-zThe experience of neck pain in people with migraine: A qualitative studyhttps://www.sciencedirect.com/science/article/pii/S1413355525003922?casa_token=9ct7RuiXWIgAAAAA:Sxlqh2wKO3-2l4ig9hzuXb92eJtttlM1Mdd3EId-5BfNQ2J8kpTn2iCd3tr6a0l58kyqDTDR7wThe impact of pain on memory: a study in chronic low back pain and migraine patients https://academic.oup.com/braincomms/article/8/1/fcaf486/8376909Migraine as a dynamic continuum during the life coursehttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00441-7/abstractNaruhodo #447 - O que é AVC e como evitá-lo? #TodosPeloPirullahttps://www.youtube.com/watch?v=vRu9cet1TWMNaruhodo #236 - Por que temos dor de cabeça?https://www.youtube.com/watch?v=q8FtXVlSz1INaruhodo #345 - Por que às vezes sentimos as dores dos outros?https://www.youtube.com/watch?v=mKdMBCqy6XANaruhodo #145 - Por que a cabeça dói quando tomamos gelado?https://www.youtube.com/watch?v=qjq2Ds6YB-cNaruhodo #165 - Quando tomo antidepressivos continuo sendo eu mesmo?https://www.youtube.com/watch?v=dWyfUyHUiA4Naruhodo #62 - Existem doenças psicossomáticas?https://www.youtube.com/watch?v=etuFYdCAKe4Naruhodo #288 - Por que existe a menopausa?https://www.youtube.com/watch?v=3Ewwdi2guWgNaruhodo #339 - Por que as coisas parecem girar quando estamos bêbados?https://www.youtube.com/watch?v=YmK1Yq0mwW8Naruhodo #398 - Jejum intermitente funciona?https://www.youtube.com/watch?v=lTkWGFFkOLo*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser. O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some fascinating updates that are shaping the future of medicine and healthcare.Let's start with a groundbreaking development in cancer treatment. Researchers have announced significant progress in a novel therapy targeting a specific mutation often found in non-small cell lung cancer. This mutation, known as EGFR exon 20 insertion, has historically been resistant to standard treatments. The new therapy employs a targeted approach that precisely inhibits the mutant protein while sparing normal cells. Early-phase clinical trials have shown promising results, with substantial tumor shrinkage observed in participants. This could potentially redefine treatment protocols for patients who previously had limited options and improve their overall survival rates. As the study progresses into later phases, the industry is watching closely to see if these initial successes translate into long-term benefits.In another significant development, we're seeing advancements in gene therapy for inherited retinal diseases. A recent study has highlighted a novel gene-editing technique that promises to restore vision in patients with certain genetic forms of blindness. By utilizing CRISPR-Cas9 technology, scientists have been able to directly correct mutations in retinal cells. The preclinical models have shown restored function and improved visual responses, paving the way for human trials. This breakthrough is not just a beacon of hope for those affected by genetic blindness but also underscores the transformative potential of gene-editing technologies in treating complex diseases.Moving on to regulatory news, there's an update on new drug approvals that could have widespread implications for public health. The FDA has recently approved a first-in-class drug for the treatment of severe migraines. This medication represents a novel mechanism of action by targeting the calcitonin gene-related peptide (CGRP) pathway, which plays a crucial role in migraine pathophysiology. Clinical trials indicated that it significantly reduces the frequency and severity of migraine attacks compared to existing treatments. For millions of sufferers worldwide, this approval offers a new avenue for relief and highlights the importance of continued innovation in chronic pain management.Shifting gears to vaccine development, there's exciting progress in the fight against infectious diseases. A new vaccine candidate for malaria has shown an unprecedented level of efficacy in trial settings. This vaccine utilizes a protein-based approach that targets multiple stages of the parasite's lifecycle, thereby enhancing its protective effects. Given malaria's devastating impact globally, particularly in sub-Saharan Africa, this development is being hailed as a potential game-changer in global health efforts. As further studies and real-world evaluations unfold, this vaccine could become a cornerstone tool in reducing malaria's burden.Now turning our attention to industry trends, there's growing momentum around personalized medicine and its integration into mainstream healthcare systems. Personalized medicine tailors treatment strategies to individual patient profiles based on genetic, environmental, and lifestyle factors. Recent advances in genomics and data analytics have accelerated this shift, allowing for more precise and effective interventions. For healthcare providers and pharmaceutical companies alike, this trend necessitates rethinking traditional drug development models and embracing collaborative approaches to harness big data effectively.Finally, let's look at an intriguing development in neurodegenerative disease research. Scientists are exploring a new class of drugs designed to target protein misfolding—an underlying cause of conditions Support the show

Send us a textWe map a practical path from “is this dangerous?” to “what actually helps." We also talk about some specific headache types such as:  IIH, medication overuse, trigeminal neuralgia as well as the rise of CGRP therapies.• separating primary from secondary headache with SNOOP4• recognizing thunderclap, GCA, IIH, and low-pressure patterns• uncovering hidden chronic headache burden and medication overuse• exam essentials including fundoscopy and neck palpation• trigeminal neuralgia in MS and targeted MRI protocols• rescue strategy with effective OTC dosing and triptan timing• antiemetic choices matched to daily function• preventives matched to sleep, anxiety, weight, and goals• carbamazepine and oxcarbazepine for trigeminal neuralgia• role of acetazolamide and topiramate in pressure states• CGRP therapies, access hurdles, and practical selection• empowering patients with education, logs, and portable plansSupport the show Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes! Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com Follow our podcast channel on

In this Faces of Digital Health episode Dr. David Dodick, Chief Science and Medical Officer at the Atria Health Institute and Co-Chair of the Atria Research Institute talks about brain health, dementia prevention, the rapidly evolving science of Alzheimer's, and how digital tools and AI are transforming care. We also cover why women face higher Alzheimer's risk, the microvasculature's role in cognition, and the biggest leap in migraine treatment: CGRP-targeting therapies. A must-watch if you're curious about prevention, personalized risk, and which consumer tech is actually useful today. Dr. David Dodick trained at the Mayo Clinic and served on the faculty there for more than three decades. At the Mayo Clinic, he founded the Neurology Residency Program, the Headache Fellowship Program, the Sports Neurology and Concussion Program, the Migraine and Headache Program, and co-founded the Vascular Neurology/Stroke Program. What you'll learn: 1. How much dementia is realistically preventable—and how to lower your risk 2. Why amyloid ≠ destiny, and what “biological vs. clinical” Alzheimer's means 3. The role of sleep, hearing, blood pressure, metabolic health, and social connection 4. Smart wearables that matter (AFib, BP, CGM) and what's just hype 5. How AI “diagnostic orchestrators” could supercharge clinicians and empower patients 6. Migraine red flags (when to go to the ER) and the CGRP revolution in treatment

What if one side of your body suddenly stopped moving — and your doctor said, “It's a migraine”?Hemiplegic migraines are rare, disorienting, and often confused with strokes. They challenge everything you think you know about how your brain, body, and energy connect.In this episode of Migraine Heroes Podcast, hosted by Diane Ducarme, we explore the science and the story behind this rare form of migraine — one that blurs the line between neurology and mystery. Together, we look at how the body can temporarily lose its flow, and how to gently help it find its rhythm again.In this episode, you'll learn:

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/not-just-a-headache-migraine-across-womens-lifespan/36591/ This session from WHAV 2025 explores the complex interplay between hormonal changes and migraine pathophysiology in women, from menarche through menopause. Faculty review diagnostic frameworks, including ICHD-3 criteria, and emphasize menstrual migraine subtypes and the role of estrogen withdrawal. Evidence-based strategies for acute and preventive treatment are discussed, including the use of CGRP receptor antagonists, hormonal therapies, and neuromodulation devices. The program also addresses disparities in care and supports shared decision-making tailored to life stage, comorbidities, and patient preferences. =

Drs. Hindiyeh and Hutchinson review new FDA-issued safety warnings for Raynaud's phenomenon and hypertension in CGRP-based migraine treatment. They explore the impact of this label update and share practical strategies for patient management.

People ask me all the time, “Does Botox work for vestibular migraine?”  Another common question people ask is, “Is it going to get rid of my dizziness?” That question is missing the point. When you're treating vestibular migraine, you're not treating the dizziness. Does Botox work for VM? Yes, but not because you're treating the dizziness. In this episode, you'll hear me synthesize a study that dove into the impact of Botox on vestibular migraine—how it works, who it works for, and some important things to know if you'd like to explore this treatment for yourself. In this episode, we'll dig into: What is Botox for and not to be used for How Botox treats vestibular migraine Where the Botox injections happen for vestibular migraine If insurance covers Botox for vestibular migraine How many Botox treatments it takes to see any change Important note if you have EDS and VM and are interested in Botox If you think Botox is just freezing the muscles and therefore vestibular migraine goes away—no. As you heard in the episode, there are way deeper things going on.  Resources referenced in this episode are linked below, so you can review them on your own and share them with your doctor. Related Episodes: Guide to CGRP Medications for VM Links/Resources Mentioned: Vestibular Group Fit (code GROUNDED at checkout!) https://pmc.ncbi.nlm.nih.gov/articles/PMC10751376/ https://pmc.ncbi.nlm.nih.gov/articles/PMC9358216/#abstract1 Blog: Vestibular Migraine: Popular Symptoms and Treatment Blog: Best 5 Tips for Managing Vestibular Migraine More Links/Resources: ⁠The 4 Steps to Managing Vestibular Migraine ⁠The PPPD Management Masterclass⁠ ⁠What your Partner Should Know About Living with Dizziness⁠ ⁠The FREE Mini VGFit Workout⁠ ⁠The FREE POTS - safe Workouts⁠ ⁠Vestibular Group Fit (code GROUNDED at checkout for 15% off your first subscription cycle!) ⁠ Connect with Dr. Madison: ⁠@⁠⁠TheVertigoDoctor ⁠ ⁠@TheOakMethod⁠ ⁠@VestibularGroupFit⁠ Connect with Dr. Jenna @dizzy.rehab.therapist  Work with Dr. Madison 1:1, Vestibular Rehabilitation Therapy Vestibular Group Fit Small Group Coaching (offered throughout the year, sign up for our email list to learn when!) Why The Oak Method? Learn about it here! Love what you heard? Reviews really help us out! Please consider leaving one for us.  This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. ————————————— botox for vestibular migraine, BPPV, PPPD, Vestibular migraine, VM, constant vestibular migraine, how to treat vestibular migraine, vestibular migraine symptoms, SSRI, will insurance cover Botox for vestibular migraine, is Botox covered by insurance, Botox foundation, vertigo attacks, episodic migraine, CGRP levels, EDS, neck strength protocol, deep cervical neck flexors

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this special edition of Mind Moments, Patricia Pozo-Rosich, MD, PhD, head of the neurology department at Vall d'Hebron University Hospital, discussed the recent FDA approval of fremanezumab (Ajovy) for pediatric migraine prevention. As a study author on the pivotal phase 3 SPACE trial (NCT03539393), Dr. Pozo-Rosich reflected on the significance of having a proven therapeutic option in a population where placebo responses and lack of evidence have long complicated care. She provided insights on how the trial was designed and the challenges of running pediatric studies, particularly in adolescents. Additionally, she highlighted broader implications for migraine research, including efforts to reduce placebo effects, the role of CGRP pathway inhibition in younger patients, and the future promise of emerging targets such as PACAP antagonists and new toxin formulations. For more of NeurologyLive's coverage of fremanezumab's expanded indication in pediatric migraine, head here: FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine Episode Breakdown: 1:10 – Initial reaction to fremanezumab approval and significant for pediatric migraine care 6:05 – Major clinical insights and takeaways from phase 3 SPACE trial 10:20 – Challenges in pediatric migraine trials and addressing high placebo responses 15:10 – Future directions in migraine therapy, including PACAP-targeting drugs and novel approaches Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

Dr. Bradley Ong shares early insights from the EMERGE trial, presented at the American Headache Society's 67th Annual Scientific Meeting in June 2025.  Show reference:  https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14957

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for August 3-9, 2025: FDA Approves Fremanezumab to Prevent Episodic Migraine in Children The FDA has expanded fremanezumab's indication to include pediatric patients 6–17 years old, making it the first CGRP antagonist approved for preventing episodic migraine in this population. ATTAIN-1: Orforglipron Achieves Up to 12% Weight Loss in Phase 3 Obesity Trial  Orforglipron, an investigational oral GLP-1 receptor agonist, met all primary and secondary endpoints in phase 3, supporting its potential as a weight-management therapy. Oral Berotralstat Shows Strong Safety, Efficacy in Young Children with HAE Interim phase 3 data support oral berotralstat as a safe and effective prophylactic therapy for hereditary angioedema in children aged 2–11 years. Aflibercept 8mg Noninferior to Aflibercept 2mg in Diabetic Macular Edema  Aflibercept 8 mg demonstrated noninferior visual acuity outcomes to 2 mg dosing in DME, with potential for reduced injection frequency. Despite Advances, IBS Continues to Impact Patients' Daily Lives, Productivity  A new national survey reveals ongoing quality-of-life and productivity burdens among IBS patients despite greater awareness and expanded treatment options.

Resources:American Migraine FoundationAmerican Migraine Foundation: Why Don't We Use the Terms "migraines," "migraine headaches" and "migraineur"?Canadian Headache Society In this episode of The Positive Pause®, host Claire Gill speaks with Claire Sandoe, MD, MSc, neurologist, educator, and American Migraine Foundation board member, for a discussion about migraine's impact on women, especially during key hormonal transitions like menopause. Dr. Sandoe shares clinical insights, recent research, and practical advice to empower women to seek help and break the stigma around migraine.Dr. Sandoe is an Assistant Professor of Medicine (Neurology) at the University of Toronto and a headache neurologist at the Women's College Hospital Centre for Headache, where she directs the City-Wide Headache Medicine Fellowship. She serves on the boards of the Canadian Headache Society and the American Migraine Foundation, the Education Committees of the International Headache Society and the American Headache Society and is co-chair of the Canadian Headache Society National Neurology Resident Headache Course as well as the American Headache Society's Mastering Migraine Therapies program.Key Points Covered:Migraine is a brain disorder, not just a headache - Migraine can include a range of symptoms like nausea, light sensitivity, brain fog, and more, even between attacks.Hormones play a major role in migraine - Estrogen fluctuations during puberty, menstruation, pregnancy, and menopause significantly affect migraine patterns in women.One in seven people globally are affected - Migraine is common, especially among women (1 in 4) but still underdiagnosed and often misunderstood.Migraine attacks vs. migraine - Dr. Sandoe explains why language matters and how "migraine attack" better reflects the episodic yet serious nature of the disorder.Migraine and menopause - Perimenopause can worsen migraine symptoms. While some women improve post-menopause, others do not, and early treatment is key.Treatment options are diverse and evolving - From lifestyle changes and supplements (like magnesium) to cutting-edge medications (like CGRP blockers) and neuromodulation devices, a range of tools are available.Trial and error are part of treatment but shouldn't mean suffering in silence - The right treatment often requires experimentation. Women should feel empowered to explore options without guilt or stigma.Stigma still exists - Migraine is often dismissed as “just a headache” or associated with outdated stereotypes of “hysterical women.” Raising awareness is vital.Migraine can worsen over time if left untreated - Dr. Sandoe compares it to a path in the brain, if traveled too often, it becomes a highway. Early treatment can prevent chronic, worsening symptoms.Resources are available - The American Migraine Foundation offers patient-friendly, clinician-verified resources on migraine, women's health, and more.Connect with the American Migraine Foundation (AMF):Website: https://americanmigrainefoundation.org Facebook: @AmericanMigraineFoundation -- https://www.facebook.com/americanmigrainefoundation &

Today on Grounded: The Vestibular Podcast, we are talking all about CGRP medications. These are a class of drugs used to manage migraine attacks. Interestingly, people with migraine have a higher level of CGRP during migraine attacks, but also have a harder time breaking them down for whatever reason. In this episode, we'll dig into: What CGRP medications are How CGRP medications work Generic names of CGRP medications How effective CGRPs are How CGRPs interact with Botox Will insurance cover CGRP medications What step therapy is and how to navigate it If a multi-pronged approach is still worth it Whether you're newly diagnosed, still searching for answers, or supporting someone with VM, this episode was created as a resource for you. Tune in and discover if we're fans of CGRPs over here… or not—and everything you need to know about these medications. Links/Resources Mentioned: Vestibular Group Fit (code GROUNDED at checkout!)  More Links/Resources: ⁠The 4 Steps to Managing Vestibular Migraine ⁠The PPPD Management Masterclass⁠ ⁠What your Partner Should Know About Living with Dizziness⁠ ⁠The FREE Mini VGFit Workout⁠ ⁠The FREE POTS - safe Workouts⁠ ⁠Vestibular Group Fit (code GROUNDED at checkout for 15% off your first subscription cycle!) ⁠ Connect with Dr. Madison: ⁠@⁠⁠TheVertigoDoctor ⁠ ⁠@TheOakMethod⁠ ⁠@VestibularGroupFit⁠ Connect with Dr. Jenna @dizzy.rehab.therapist  Work with Dr. Madison 1:1, Vestibular Rehabilitation Therapy Vestibular Group Fit Small Group Coaching (offered throughout the year, sign up for our email list to learn when!) Why The Oak Method? Learn about it here! Love what you heard? Reviews really help us out! Please consider leaving one for us.  This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. ————————————— vestibular migraine, VM, CGRP medications, CGRPs for migraine, calcitonin gene-related peptides, migraine disorder, migraine attacks, preventative CGRP, acute CGRP, Aimovig, Ajovy, CGRP injections, Vyepti, Ubrelvy, oral CGRP, are CGRPs covered by insurance, step therapy, comprehensive migraine treatment

It's important to know the progression of muscle fiber dysfunction to better understand how to treat and how long it may take to correct the problem.   The analysis of current research provides substantial evidence supporting the progression of muscle fiber dysfunction as a significant contributor to musculoskeletal pain, aligning with the hypothesized sequence: sustained muscle tone leading to long-term muscle fiber shortening, which subsequently culminates in painful myofascial trigger points. The initial phase of this progression is rooted in the transition from normal physiological muscle tone to a state of pathological hypertonia or chronic muscle overload. Sustained low-level muscle contractions, even at submaximal levels, are shown to generate sufficient intramuscular pressure to compromise local capillary blood flow. This circulatory impairment leads to localized ischemia and hypoxia within the muscle fibers, precipitating a critical "energy crisis" due to insufficient ATP production. This energy deficit is pivotal for the subsequent development of muscle fiber shortening. ATP is indispensable not only for muscle contraction but also for the crucial process of muscle relaxation, specifically for the detachment of myosin heads from actin and the re-uptake of calcium ions. When ATP is depleted, these relaxation mechanisms fail, resulting in sarcomeres becoming locked in a state of sustained, pathological hypercontraction. This localized shortening at the sarcomere level forms the palpable "taut band" that is a hallmark of myofascial trigger points. Over extended periods, such sustained pathological shortening can also contribute to broader structural changes like muscle contractures, involving fibrosis and a permanent reduction in muscle length. The culmination of this progression is the development of painful trigger points. The sustained sarcomere hypercontraction, driven by the energy crisis and calcium dysregulation, creates a severely acidic local environment. This acidic milieu, coupled with tissue injury from prolonged ischemia, triggers the release and accumulation of various neuroactive and inflammatory mediators. These substances directly stimulate and sensitize muscle nociceptors, manifesting as the exquisite tenderness and characteristic referred pain associated with active myofascial trigger points. Furthermore, the pathophysiology of myofascial trigger points is characterized by a complex, self-perpetuating vicious cycle. The energy crisis and subsequent acidic environment inhibit acetylcholinesterase, leading to prolonged acetylcholine effects and further sustained muscle contraction. Concurrently, mediators like calcitonin gene-related peptide (CGRP) not only potentiate muscle contraction but also directly activate nociceptors. This intricate feedback loop ensures the chronicity of the condition, as the consequences of muscle shortening directly exacerbate the initial problem of sustained contraction and pain. This comprehensive understanding of the progression from sustained muscle tone to muscle shortening and painful trigger points has significant implications for both clinical practice and future research in musculoskeletal pain. For clinicians, it underscores the importance of early identification and intervention for chronic muscle tension and overuse, aiming to disrupt the energy crisis cycle before fixed structural changes or chronic pain states become entrenched. Therapeutic strategies should not only target pain relief but also address the underlying metabolic and biomechanical dysfunctions, including restoring proper muscle length, improving local circulation, and resolving the energy deficit. For researchers, the identified roles of specific molecules like CGRP and the intricate feedback loops within the "energy crisis" model present promising avenues for developing novel diagnostic markers and targeted pharmacological or rehabilitative interventions that can effectively break the self-perpetuating cycle of myofascial pain.   Online Courses: https://richardhazel.podia.com    

Story at-a-glance Women with chronic migraines and body-wide pain were far more likely to have poor oral health, with over half falling into the lowest oral health categories in a new study Specific oral bacteria, including Mycoplasma salivarium and Gardnerella vaginalis, were significantly more common in women who reported frequent migraines and widespread pain Harmful oral microbes don't stay in your mouth; once gum tissue is inflamed, these bacteria enter your bloodstream, disrupt the immune system, and trigger systemic pain A less diverse oral microbiome was found in women with migraines and gut pain, making it easier for pain-triggering bacteria to dominate and inflame nerve pathways Inflammatory chemicals produced by oral bacteria — like calcitonin gene-related peptide (CGRP) and vascular endothelial growth factor (VEGF) — are directly involved in migraine and fibromyalgia, showing how poor oral hygiene can set off whole-body pain responses

Drs. VanderPluym and Starling review the updated position statement from the American Headache Society indicating that CGRP-targeting migraine therapies should be considered as a first-line option.

Text Dr. Lenz any feedback or questions This episode dives into the complex relationship between migraines and hormonal changes, particularly focusing on estrogen. The discussion covers the prevalence of migraines, the distinction between migraines with and without aura, and the significant impact of reproductive hormones on migraine patterns, especially in women. Key topics include the discovery of the estrogen threshold, the influence of estrogen on neurotransmitter systems like serotonin and glutamate, and the potential of hormone-based treatments. The episode also examines the role of the trigeminal vascular system, calcitonin gene-related peptide (CGRP), and the impact of oral contraceptives on migraine frequency and intensity. Practical strategies for managing menstrual migraines and the importance of using headache diaries for accurate diagnosis are highlighted.00:00 Introduction to Migraines00:20 Types of Migraines and Auras00:42 Sex Differences in Migraine Prevalence00:59 Hormonal Influence on Migraines01:53 Estrogen's Role in Menstrual Migraines02:05 Historical Breakthroughs in Migraine Research02:35 Estrogen Threshold and Migraine Triggers04:10 Estrogen's Impact on Brain Function07:29 Neurotransmitters and Migraine Pathways11:15 Oxytocin and Migraine Prevention13:20 Trigeminal Vascular System and Migraines16:46 Calcitonin Gene-Related Peptide and Inflammation20:38 Oral Contraceptives and Migraine Management24:59 The Importance of Headache Diaries26:45 Conclusion and Future Research Click here for the Fibromyalgia 101 link.Click here to connect with Joy Lenz. Support the showWhen I started this podcast—and the book that came before it—I had my patients in mind. Office visits are short, but understanding complex, often misunderstood conditions like fibromyalgia takes time. That's why I created this space: to offer education, validation, and hope. If you've been told fibromyalgia “isn't real” or that it's “all in your head,” know this—I see you. I believe you. You're not alone. This podcast aims to affirm your experience and explain the science behind it. Whether you live with fibromyalgia, care for someone who does, or are a healthcare professional looking to better support patients, you'll find trusted, evidence-based insights here, drawn from my 28+ years as an MD. Please remember to talk with your doctor about your symptoms and care. This content doesn't replace personal medical advice.* ...

We are kicking off the new year and a new season with a great guest! Dr. Kristen Steenerson, MD brings her expertise to the conversation with a deeper dive into Vestibular Migraine and Persistent Postural Perceptual Dizziness. Whether you're a patient or a clinician, you surely don't want to skip this episode! Kristen K. Steenerson, MD is a board-certified neurologist with fellowship training in vestibular neurology. She graduated cum laude from Claremont McKenna College, received her MD from the University of Utah, completed neurology residency at Mayo Clinic Arizona, and fellowship at Barrow Neurological Institute. She directs the Vestibular Balance Disorders Program of the Stanford Balance Center. She has joint appointments in the departments of Otolaryngology--Head and Neck Surgery and Neurology & Neurological Sciences at Stanford. Her clinical interests include vestibular migraine, persistent postural-perceptual dizziness, benign paroxysmal positional vertigo, Ménière's disease, and international neurology. Episode Resources - Central and peripheral vestibular disorders overview (and how much they overlap!): https://www.nature.com/articles/nrneurol.2017.58 - CGRP position paper: https://pubmed.ncbi.nlm.nih.gov/38466028/ - VMPATHI survey:https://redcap.ucsf.edu/surveys/?s=CY893NJHCM - VMPATHI paper: https://pubmed.ncbi.nlm.nih.gov/32176141/ - Comprehensive analysis of VM treatments: https://pubmed.ncbi.nlm.nih.gov/35859353/ - Migraine influences tinnitus and hearing loss: https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/ohn.201?casa_token=pfzZz62NjqcAAAAA:u0enZoqzF6n8D1_o_7G4HyTY5qpjFd0cDutwNpFtigKXd7xo4Zo65Cuzy4qZWjHDeuMICp0RYuKrGQ - Cognitive failures improve when migraine improves: https://pubmed.ncbi.nlm.nih.gov/37525385/ - Treat MdDS as migraine: https://pmc.ncbi.nlm.nih.gov/articles/PMC5823515/ - Magazine article: https://www.bustle.com/p/what-actually-happens-in-your-brain-when-you-have-a-migraine-according-to-experts-16823975 Hosted by Dr. Abbie Ross, PT, NCS, and Dr. Danielle Tolman, PT For Episode Recommendations or Requests, email us info@balancingactrehab.com Where to find us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://link.me/balancingactrehab⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.BalancingActRehab.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠Facebook: @BalancingActRehab Instagram: @BalancingActRehab Twitter: @DizzyDoctors TikTok: @BalancingActRehab